Cilostazol ameliorates high free fatty acid (FFA)-induced activation of NLRP3 inflammasome in human vascular endothelial cells

References

• Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328–338.
   PubMed Web of Science ®Google Scholar
• Sharma A, Tate M, Mathew G, et al. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol. 2018;9:114.
   PubMed Web of Science ®Google Scholar
• Lebreton F, Berishvili E, Parnaud G, et al. NLRP3 inflammasome is expressed and regulated in human islets. Cell Death Dis. 2018;9(7):726
   PubMed Web of Science ®Google Scholar
• Abderrazak A, El Hadri K, Bosc E, et al. Inhibition of the Inflammasome NLRP3 by arglabin attenuates inflammation, protects pancreatic β-cells from apoptosis, and prevents type 2 diabetes mellitus development in ApoE2Ki mice on a chronic high-fat diet. J Pharmacol Exp Ther. 2016;357(3):487–494.
   PubMed Web of Science ®Google Scholar
• Shao B-Z, Xu Z-Q, Han B-Z, et al. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27(6):423–431.
   PubMedGoogle Scholar
• Weintraub WS. The vascular effects of cilostazol. Can J Cardiol. 2006;22:56B–60B.
   PubMed Web of Science ®Google Scholar
• Aoki C, Hattori Y, Tomizawa A, et al. Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo. J Atheroscler Thromb. 2010;17(5):503–509.
   PubMed Web of Science ®Google Scholar
• Ahn C, Lee H, Park S, et al. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2001;52(1):45–53.
   PubMed Web of Science ®Google Scholar
• Spiller S, Blüher M, Hoffmann R. Plasma levels of free fatty acids correlate with type 2 diabetes mellitus. Diabetes Obes Metab. 2018;20(11):2661–2669.
   PubMed Web of Science ®Google Scholar
• Legrand-Poels S, Esser N, L’Homme L, et al. Free fatty acids as modulators of the NLRP3 Inflammasome in obesity/type 2 diabetes. Biochem Pharmacol. 2014;92(1):131–141.
   PubMed Web of Science ®Google Scholar
• Qi Y, Du X, Yao X, et al. Vildagliptin inhibits high free fatty acid (FFA)-induced NLRP3 inflammasome activation in endothelial cells. Artif Cells Nanomed Biotechnol. 2019;47(1):1067–1074.
   PubMed Web of Science ®Google Scholar
• Kuroda J, Ago T, Matsushima S, et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA. 2010;107(35):15565–15570.
   PubMed Web of Science ®Google Scholar
• Wang L, Li X, Zhang Y, et al. Oxymatrine ameliorates diabetes-induced aortic endothelial dysfunction via the regulation of eNOS and NOX4. J Cell Biochem. 2018;120:7323–7332
   PubMed Web of Science ®Google Scholar
• Mohamed IN, Hafez SS, Fairaq A, et al. Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia. 2014;57(2):413–423.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lian K, Zhang L, et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2014;109(5):415.
   PubMed Web of Science ®Google Scholar
• Shah A, Xia L, Goldberg H, et al. Thioredoxin-interacting protein mediates high glucose-induced reactive oxygen species generation by mitochondria and the NADPH oxidase, Nox4, in mesangial cells. J Biol Chem. 2013;288(10):6835–6848.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhong J, Zhang X, et al. The role of HMGB1 in the pathogenesis of type 2 diabetes. J Diabetes Res. 2016;2016:1–11.
   Web of Science ®Google Scholar
• Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006;83(2):447S–455S
   PubMed Web of Science ®Google Scholar
• Van de Veerdonk FL, Netea MG, Dinarello CA, et al. Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol. 2011;32(3):110–116.
   PubMed Web of Science ®Google Scholar
• Ota H, Akishita M, Eto M, et al. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol. 2007;43(5):571–579.
   PubMed Web of Science ®Google Scholar
• Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy. Cardiovasc Toxicol. 2001;1(3):181–193.
   PubMedGoogle Scholar
• Kayama Y, Raaz U, Jagger A, et al. Diabetic cardiovascular disease induced by oxidative stress. IJMS. 2015;16(10):25234–25263.
   Web of Science ®Google Scholar
• Xiao M, Zhong H, Xia L, et al. Pathophysiology of mitochondrial lipid oxidation: role of 4-hydroxynonenal (4-HNE) and other bioactive lipids in mitochondria. Free Radic Biol Med. 2017;111:316–327.
   PubMed Web of Science ®Google Scholar
• Xie X, Xu X, Sun C, et al. Protective effects of cilostazol on ethanol-induced damage in primary cultured hepatocytes. Cell Stress Chaperones. 2018;23(2):203–211.
   PubMed Web of Science ®Google Scholar
• Mihalas BP, De Iuliis GN, Redgrove KA, et al. The lipid peroxidation product 4-hydroxynonenal contributes to oxidative stress-mediated deterioration of the ageing oocyte. Sci Rep. 2017;7(1):6247.
   PubMed Web of Science ®Google Scholar
• Ding C, Zhao Y, Shi X, et al. New insights into salvianolic acid A action: regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats. Sci Rep. (1) 2016;6:28734.
   PubMed Web of Science ®Google Scholar
• Frank MG, Weber MD, Fonken LK, et al. The redox state of the alarmin HMGB1 is a pivotal factor in neuroinflammatory and microglial priming: a role for the NLRP3 inflammasome. Brain Behav Immun. 2016;55:215–224.
   PubMed Web of Science ®Google Scholar
• Chang KC. Cilostazol inhibits HMGB1 release in LPS-activated RAW 264.7 cells and increases the survival of septic mice. Thromb Res. 2015;136(2):456–464.
   PubMed Web of Science ®Google Scholar
• de Franciscis S, Gallelli L, Battaglia L, et al. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. Int Wound J. 2015;12(3):250–253.
   PubMed Web of Science ®Google Scholar
• Moreira HS, Lima-Leal GA, Santos-Rocha J, et al. Phosphodiesterase-3 inhibitor cilostazol reverses endothelial dysfunction with ageing in rat mesenteric resistance arteries. Eur J Pharmacol. 2018;822:59–68.
   PubMed Web of Science ®Google Scholar
• Lee HR, Shin HK, Park SY, et al. Cilostazol upregulates autophagy via SIRT1 activation: reducing amyloid-β peptide and APP-CTFβ levels in neuronal cells. PloS One. 2015;10(8):e0134486.
   PubMed Web of Science ®Google Scholar
• Park SY, Lee SW, Kim HY, et al. Suppression of RANKL-induced osteoclast differentiation by cilostazol via SIRT1-induced RANK inhibition. Biochim Biophys Acta. 2015;1852(10):2137–2144.
   PubMed Web of Science ®Google Scholar
• Kabil SL. Beneficial effects of cilostazol on liver injury induced by common bile duct ligation in rats: role of SIRT 1 signaling pathway. Clin Exp Pharmacol Physiol. 2018;45(12):1341–1350.
   PubMed Web of Science ®Google Scholar